Pinning Down Presbyopia Management: Understanding Patient Needs (CE Monograph)

Activity Description and Purpose

Presbyopia is a common cause of visual impairment affecting most adults aged ≥ 40 years. Limitations of conventional methods for presbyopia correction have spurred the development of topical pharmacologic agents as an alternative intervention, with major focus on medications that employ the principles of small aperture optics by inducing miosis. One pharmacologic treatment for presbyopia is already commercially available, another product is undergoing regulatory review for licensing, and others are advancing through clinical trials. This is Part 1 of a 2-part educational activity series designed to enable optometrists to successfully implement pharmacologic treatments for presbyopia for appropriately selected patients. Part 1 reviews conventional treatments for presbyopia and presents an overview of the mechanisms of accommodation, presbyopia, and small aperture (pinhole) optics to provide a foundation for understanding the efficacy of pharmacologic treatments for presbyopia and counseling patients on these products.

Target Audience

This educational activity is intended for optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Review limitations of conventional treatment options for presbyopia
  • Describe the mechanisms of accommodation
  • Review the principles of pinhole optics in the improvement of near vision
  • Integrate education on presbyopia into patient counseling

You may also be interested in

Pinning Down Presbyopia Management: New and Emerging Pharmacologic Treatments (CE Monograph)
This is Part 2 of a 2-part educational activity series designed to enable optometrists to successfully implement pharmacologic treatments for presbyopia for appropriately selected patients.
Course summary
Available credit: 
  • 1.00 COPE
Course opens: 
04/28/2023
Course expires: 
04/30/2024

Faculty

Paul Karpecki, OD, FAAO (Chair)
Director, Cornea and External Disease
Kentucky Eye Institute
Lexington, Kentucky
Associate Professor
University of Pikeville School of Optometry
Pikeville, Kentucky
Nathan Lighthizer, OD
Associate Dean and Associate Professor
Chief, Specialty Care Clinics
Northeastern State University College of Optometry
Tahlequah, Oklahoma
Gina Wesley, OD, MS
Complete Eye Care of Medina
Medina, Minnesota

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.

Faculty

Paul Karpecki, OD, is a consultant for AbbVie Inc, Akorn, Inc, Alcon, Aldeyra Therapeutics, Allergan, Ametek, Inc, Atlas Medical GmbH, Avellino, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bio-Tissue, BlephEx, Bruno Vision, Cambium Medical Technologies, Dompé US, Inc, Gobiquity, Haag-Streit Group, Hilco Vision, Icare USA Inc, Imprimis Pharmaceuticals, Inc, Kala Pharmaceuticals, Kiora Pharmaceuticals, Inc, Konan Medical USA, Inc, Lentechs, Neurolens, Novartis Pharmaceuticals Corporation, OASIS Medical, OCULUS, Inc, OCuSOFT Inc, Optase, Oyster Point Pharma, Inc, Rendia, Inc, RVL Pharmaceuticals, Inc, RxSIGHT, ScienceBased Health, Sentiss Pharma Pvt Ltd, Sight Sciences, StepWise Medical, LLC, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, Thea Pharmaceuticals Limited, Visant Medical, Inc, Vital Tears LLC, and Zeiss; is on the speakers bureau for Aerie Pharmaceuticals, Johnson & Johnson Vision Care, Inc, Mallinckrodt; is an advisory board member of AstaReal, Inc; and has stock options that have not been exercised in SilkTech Biopharmaceuticals.

Nathan Lighthizer, OD, is a consultant for Diopsys, Inc, and OCuSOFT Inc; is on the speakers bureau for Dompé US, Inc, Ellex, and Sun Pharmaceutical Industries, Inc; and is an advisory board member of Bruder Healthcare, Horizon Therapeutics plc, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, Inc, Sight Sciences, and ZeaVision LLC.

Gina Wesley, OD, MS, is a consultant for Bausch & Lomb Incorporated, Lumenis, and Orasis Pharmaceuticals, Inc; and is a contracted researcher for Alcon, CooperVision, and Johnson& Johnson Vision Care, Inc.

Planners, Managers, and Writers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

Medical Writer: Cheryl Guttman Krader has individual stocks in Johnson & Johnson Vision Care, Inc.

Accreditation Statement

COPE approved for 1.0 CE credit for optometrists.
COPE Course ID: 84149-GO (Asynchronous)
COPE Course Category: General Optometry

Administrator:

Disclosure of Commercial Support

This continuing education activity is supported through an educational grant from Orasis Pharmaceuticals, Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Sponsored by

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, or Orasis Pharmaceuticals, Inc.

This CE activity is copyrighted to MedEdicus LLC ©2023. All rights reserved. 285.1

Available Credit

  • 1.00 COPE
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CE information for this activity.